Silexion Therapeutics LTD

0.96
-0.03 (-3.23%)
At close: Apr 03, 2025, 1:52 PM

Company Description

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.

The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.

Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.

The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Silexion Therapeutics LTD
Silexion Therapeutics LTD logo
Country IL
IPO Date Aug 16, 2024
Industry Biotechnology
Sector Healthcare
Employees n/a
CEO Ilan Hadar M.B.A.

Contact Details

Address:
The Goldyne Savad Institute of Gene Therapy
Jerusalem,
IL
Website https://silexion.com

Stock Details

Ticker Symbol SLXN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0002022416
CUSIP Number n/a
ISIN Number KYG1281K1067
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Ilan Hadar M.B.A. Chairman & Chief Executive Officer
Mirit Horenshtein Hadar EVice President of Finance Affairs, Chief Financial Officer & Secretary
Dr. Mitchell Shirvan M.B.A., Ph.D. Chief Scientific & Development Officer

Latest SEC Filings

Date Type Title
Apr 01, 2025 424B3 Filing
Mar 28, 2025 8-K Current Report
Mar 27, 2025 S-1/A [Amend] Filing
Mar 18, 2025 S-8 Filing
Mar 18, 2025 8-K Current Report
Mar 18, 2025 10-K Annual Report
Mar 14, 2025 424B3 Filing
Mar 14, 2025 8-K Current Report
Mar 05, 2025 8-K Current Report
Feb 12, 2025 S-1 Filing